$SABS News

SAB Biotherapeutics Highlights Diabetes Trial Progress, Human Antibody Platform

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes

FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes

SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics Q2 Earnings Call Highlights

SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ...

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 Diabetes

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)

Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12